Sanofi SA


  • Sanofi to spare Toulouse in restructuring - minister Wednesday, 10 Oct 2012 | 11:48 AM ET

    PARIS, Oct 10- French drug maker Sanofi has dropped plans to exit its research laboratory in the southern town of Toulouse as part of a reorganisation of its French research operations, Industry Minister Arnaud Montebourg said on Wednesday.

  • Oct 9- Regulus Therapeutics Inc:. *Sanofi reports 10.99% passive stake in Regulus Therapeutics Inc as. of October 4- SEC filing* Source text:.

  • Earnings concerns hit UK shares, uptrend intact Monday, 8 Oct 2012 | 1:00 PM ET

    *FTSE 100 index finishes 0.5 percent lower. *Charts signal FTSE's uptrend intact. were down 0.4 percent after the World Bank cut its growth forecasts for China and as investors prepared for third-quarter earnings, which kick off on Tuesday in the United States with results from aluminium company Alcoa.

  • LONDON, Oct 8- Sanofi Pasteur MSD, the vaccine joint venture of Sanofi and Merck& Co, has recalled some batches of its typhoid vaccine because of concerns about effectiveness, Britain's drug regulator said on Monday.

  • Sanofi to buy back Genzyme-linked CVRs for $70 mln Monday, 8 Oct 2012 | 6:20 AM ET

    PARIS, Oct 8- French drugmaker Sanofi said on Monday it will buy back certificates related to the success of Genzyme drugs for a total cost of about $70 million, representing $1.75 per contingent value right. Sanofi said last month it would buy back up to $152 million worth of the outstanding CVRs, which are linked to its 2011 purchase of U.S. biotech Genzyme.

  • ended slightly lower on Friday, breaking a four-session winning run, while the MSCI broad index of Asia Pacific shares outside Japan. on Tuesday, and after the World Bank cut its economic growth forecasts for the East Asia and Pacific region, warning about risks the slowdown in China could get worse and last longer than expected.

  • French and Benelux stocks-Factors to watch on Oct 8 Monday, 8 Oct 2012 | 1:28 AM ET

    Britain will block the proposed $45 billion merger between EADS and BAE Systems if key "red line" priorities are not met, defence minister Philip Hammond said on Sunday, just three days before a deadline for detailing the deal.

  • *Unions predict more layoffs than 900 cuts mooted by Sanofi. PARIS, Oct 5- Sanofi's plan to restructure its research operations in France could lead to more job losses than the 900 layoffs mooted by the drugmaker, union representatives said.

  • PARIS, Oct 5- French automaker Renault plans to build more than 70 percent of its Clio subcompacts in Turkey, union sources said, in a shift abroad that could inflame tensions with workers and the government, its biggest shareholder.

  • French and Benelux stocks-Factors to watch on Oct 5 Friday, 5 Oct 2012 | 1:13 AM ET

    EADS and BAE Systems have edged closer towards winning political backing for a $45 billion merger amid positive signals from Britain and France, but German misgivings over control remain a major hurdle, sources close to the talks said.

  • "We anticipate that Denmark- based Novo Nordisk A/S, already the global market leader in diabetic treatments, could jump into the top 10 global pharmaceutical companies in revenue terms over the next few years, while presently it is still a midsize company compared with its peers and specializes almost exclusively on diabetes treatments," said Standard& Poor's credit analyst Olaf Toelke.

  • News Summary: Bristol-Myers, Sanofi alter alliance Wednesday, 3 Oct 2012 | 3:18 PM ET

    NEW DEAL: Bristol-Myers Squibb and France's Sanofi are revamping their longtime partnership marketing some of their best-selling medications, blood thinner Plavix and blood pressure drugs Avapro and Avalide. THE TERMS: Bristol-Myers will keep selling Plavix in the U.S. through December 2019.

  • Bristol-Myers, Sanofi revamp Plavix sales alliance Wednesday, 3 Oct 2012 | 11:41 AM ET

    TRENTON, N.J.-- Bristol-Myers Squibb Co. and Sanofi SA said Wednesday that they are restructuring their longtime partnership selling popular heart medications, now that their sales are plunging due to recent, widespread competition from generic versions.

  • *Bristol to return rights to Plavix, Avapro to Sanofi. *Sanofi to make $200 mln terminal payment to Bristol in 2018. *Sanofi shares down 0.8 pct By James Regan.

  • LONDON, Oct 3- European stocks were set for a slightly lower open on Wednesday as new gloomy economic data and uncertainty about Spain's debt crisis eclipsed underlying optimism about coordinated monetary support from central banks across the world.

  • Sanofi, Bristol shake up alliance as patents end Wednesday, 3 Oct 2012 | 1:46 AM ET

    This will give Sanofi sole commercial control of the two treatments, although Bristol-Myers will keep rights to Plavix in the United States and Puerto Rico. In return, Sanofi will pay Bristol-Myers royalty payments through 2018 on its sales of branded and unbranded Plavix worldwide, excluding the U.S. and Puerto Rico, and on sales of Avapro/Avalide.

  • French and Benelux stocks-Factors to watch on Oct. 3 Wednesday, 3 Oct 2012 | 12:59 AM ET

    Ipsen said that Inspiration Biopharmaceuticals had not raised third-party financing by the contractual deadline of Sept. 30 and that it was therefore no longer obligated to pay the additional $12.5 million in exchange for Inspiration equity. The parties continue to explore various options, Ipsen said.

  • PARIS, Oct 3- A quest by President Francois Hollande to show he can halt industrial closures by rescuing two mothballed blast furnaces in northeast France risks backfiring, with industry experts doubting any buyer will come forward. With joblessness at over 10 percent and his ratings in free-fall, Hollande persuaded steel giant ArcelorMittal.

  • PARIS, Oct 2- Sanofi's Lyxumia experimental diabetes treatment can slow down the rate at which food passes and can reduce blood sugar levels after a meal when given in combination with other diabetes drugs, the drugmaker said in a statement on Tuesday.

  • Sanofi says Lyxumia diabetes drug studies positive Tuesday, 2 Oct 2012 | 6:21 AM ET

    PARIS, Oct 2- Sanofi's experimental diabetes treatment Lyxumia can slow down the rate at which food passes and can reduce blood sugar levels after a meal when given in combination with other diabetes drugs, the drugmaker said in a statement on Tuesday.